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Abstract
Background: Bladder cancer (BC) is one of the most common cancers in the western world and ranks as the most
expensive to manage, due to the need for cystoscopic examination. BC shows frequent changes in DNA
methylation, and several studies have shown the potential utility of urinary biomarkers by detecting epigenetic
alterations in voided urine. The aim of this study is to develop a targeted bisulfite next-generation sequencing assay
to diagnose BC from urine with high sensitivity and specificity.
Results: We defined a 150 CpG loci biomarker panel from a cohort of 86 muscle-invasive bladder cancers and 30
normal urothelium. Based on this panel, we developed the UroMark assay, a next-generation bisulphite sequencing
assay and analysis pipeline for the detection of bladder cancer from urinary sediment DNA. The 150 loci UroMark
assay was validated in an independent cohort (n = 274, non-cancer (n = 167) and bladder cancer (n = 107)) voided
urine samples with an AUC of 97%. The UroMark classifier sensitivity of 98%, specificity of 97% and NPV of 97% for
the detection of primary BC was compared to non-BC urine.
Conclusions: Epigenetic urinary biomarkers for detection of BC have the potential to revolutionise the management
of this disease. In this proof of concept study, we show the development and utility of a novel high-throughput,
next-generation sequencing-based biomarker for the detection of BC-specific epigenetic alterations in urine.
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Background
Bladder cancer represents one of the most common ma-
lignancies in the western world, ranking 8th in incidence
and ranks 13th in terms of cancer mortality worldwide
[1]. Cystoscopy is the gold standard test for the detection
of bladder cancer, but it is operator-dependent with a sen-
sitivity of 90–97% [2–6]. However, cystoscopy is an inva-
sive procedure requiring clinic or hospital attendance and
poses a small but significant risk of infection [7]. Although
the sensitivity of cystoscopy is less than absolute, patient
perception of the test is such that the performance of an
alternative (such as a non-invasive) test should have a sen-
sitivity of 95% or greater [8].
Bladder cancer carries a significant health economic
burden in the UK, with the management of bladder
cancer costing in excess of £55M/year [9, 10]. A signifi-
cant proportion of that cost is due to the need for cyst-
oscopy to rule out the presence of cancer. Over 110,000
cystoscopies are performed each year in the UK for pa-
tients presenting with haematuria, and a similar num-
ber for surveillance cystoscopies are performed for
known non-muscle-invasive bladder cancer patients.
However, given that only 10% of haematuria patients
undergoing cystoscopy will have a diagnosis of bladder
cancer, a non-invasive assay which can rule out the
presence of cancer with a high degree of certainty will
not only reduce the economic burden of cystoscopy,
but also minimise the requirement for this invasive
procedure in the majority of patients without cancer
[9, 10]. Although several commercial assays have FDA
* Correspondence: a.feber@ucl.ac.uk
1UCL Cancer Institute, University College London, London, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Feber et al. Clinical Epigenetics  (2017) 9:8 
DOI 10.1186/s13148-016-0303-5
approval for the detection of bladder cancer from urine,
none are approved as stand-alone tests to replace cystos-
copy [11]. This includes urine cytology, which is frequently
used as a diagnostic aid in conjunction with cystoscopy,
but as with the other commercial assays, has low sensitivity
to detect cancer other than high-grade disease, and carcin-
oma in situ thus cannot replace cystoscopy [12, 13].
Changes in DNA methylation play a key role in
malignant transformation, leading to the silencing of
tumour suppressor genes and overexpression of onco-
genes [14]. Despite its plasticity, DNA methylation is
ontogenically relatively stable, a property which can be
exploited to develop diagnostic assays resulting in an
active area of research in the field of urinary-based bio-
markers for the non-invasive detection of bladder can-
cer [15–18]. To date, DNA methylation biomarker
panels have contained a relatively small number of loci,
in part due to technological limitations and the require-
ment to retain diagnostic specificity [11–19]. Although
these panels have shown promise [19], they have in
general not reached the required sensitivity to replace
cystoscopy with an inherent weakness being the limited
number of targets included to maintain specificity [19–24].
More recently, assays based on mutation and methylation
targets have shown high sensitivity but remain to be vali-
dated [20, 25].
Emerging techniques that utilise next-generation DNA
sequencing (NGS) hold particular promise for the devel-
opment of highly sensitive epigenetic biomarker panels.
For example, the microdroplet-based PCR amplification
of bisulfite-converted DNA followed by NGS of the
amplified target loci (termed RainDrop BS-Seq) enables
the sensitive, specific and simultaneous amplification of
up to 4000 bisulfite-converted target loci [26]. We and
others have shown the utility of this approach to validate
epigenetic alterations in a range of tissues [27–29]. In
this proof of concept study, we describe the develop-
ment of the UroMark assay, which uses high-throughput
targeted bisulphite sequencing of urinary sediment cell
DNA to provide a read-out of presence or absence of
bladder cancer. This assay, in which a large comprehen-
sive panel shows diagnostic precision, achieving high
sensitivity and specificity for disease detection, would
represent a potential paradigm shift in the diagnosis and
surveillance of bladder cancer.
Methods
Study population
Genome-wide DNA methylation profiling was performed
on DNA from 86 bladder cancers and 30 age-matched
normal urothelium samples obtained from biorepositories
at the University College London Hospitals (UCLH) and
the University of Birmingham Bladder Cancer Prognosis
Program (BCPP) (cohort 1, Table 1). Pathological review
of representative haematoxylin and eosin (H&E) sections
was conducted to include only specimens with tumour
cellularity >80%. Blood methylome data was retrieved
from the MARMAL-aid database (http://marmal-aid.org,
[30]). Normal urothelium samples were taken from non-
bladder cancer patients by urothelial brushings to ensure
a true reflection of the normal urothelium and limit con-
tamination from underlying stroma and muscle.
For target validation, cohort 2 (n = 199) was an independ-
ent dataset obtained from The Cancer Genome Atlas
(TCGA) (https://tcga-data.nci.nih.gov/tcga/dataAccessMa
trix.htm?mode=ApplyFilter&showMatrix=true&disease
Type=BLCA&tumorNormal=TN&tumorNormal=T&
tumorNormal=NT&platformType=2&platformType=42).
This contains data for 144 muscle-invasive bladder cancers
and 20 normal urothelium samples. We supplemented the
TCGA data with a further 35 methylomes generated from
non-muscle-invasive disease, representative of low-grade
disease from the Centro de Investigaciones Energéticas,
Medioambientales y Tecnológicas (CIEMAT) (Madrid)
(cohort 2, Table 1).
Cohorts 3 and 4 comprised voided urine samples ob-
tained from the patients attending the UCLH for inves-
tigation of haematuria and surveillance cystoscopy.
Haematuria cases were investigated by cystoscopy and
upper tract imaging as standard of care [31]. A visual
diagnosis of cancer was confirmed by tumour resection
and histopathological analysis. Voided urine samples
were obtained between January 2012 and 2016 (cohorts 3
and 4 (Table 2)), and the urinary sediment was pelleted
and stored at −80 °C. Cohort 3 (n = 86) comprised 52 con-
firmed bladder cancer and 34 non-bladder cancer cases.
Cohort 4 (n = 205) comprised 55 bladder cancer and 133
non-bladder cancer cases. The cellular content of urine
samples was pelleted by centrifugation at 1500g for
10 min and the supernatant removed. Urinary DNA was
Table 1 Patient characteristics of primary tissues used in (cohort 1)
discovery and (cohort 2) validation
Cohort 1 (N = 116) Cohort 2 (N = 199)
Cancer 86 179
Age 68 (32–90) 68 (34–88)
Gender
Male/Female 52/34 132/47
Ta–T1 16 35
T2–T4 70 144
Low grade 12 35
High grade 74 144
Non-cancer 30 20
Age 62 (45–86) 67 (41–82)
Gender
Male/Female 22/8 23/7
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extracted using a DNeasy Blood and Tissue Kit (Qiagen).
The cell pellet was washed with PBS and repelleted, and
the supernatant was removed and the pellet resuspended
in 200 μL fresh PBS. The samples were digested with
Proteinase K and incubated at 56 °C for 10 min, and
200 μL of absolute ethanol was added before transfer to
DNeasy columns. DNA was extracted according to the
manufacturer’s instructions and finally eluted in 100 μL of
Buffer AE (Qiagen). The DNA was quantified by spectro-
photometry (Nanodrop 1000) and fluorimetry (Qubit
dsDNA HS Assay Kit, Invitrogen). The DNA integrity was
assessed using a Bioanalyzer (Agilent Technologies).
Ethics approval
The studies were conducted under the following ethics ap-
provals: For primary tissue obtained at UCLH (10/H1306/
42, 15/YH0311), BCPP (06/MRE04/65) and Madrid (CEIC
10/50); and urinary validation: 06/Q0104/57, 10/H1306/42
and 15/YH0311.
Genome-wide methylation profiling
Five hundred nanograms of DNA was bisulfite-converted
and hybridised to the Infinium 450K Human Methylation
array (Illumina) and processed in accordance with the
manufacturer’s recommendations. DNA bisulfite conver-
sion was carried out using the EZ DNA Methylation Kit
(Zymo Research) as per manufacturer’s instructions. The
R statistical software (version 3.1.2 [32]) was used for the
subsequent data analysis. The ChAMP analysis pipeline
was used to extract and analyse data from iDat files
[33]. Samples were normalised using BMIQ [33, 34].
Raw β-values (methylation value) were subjected to a
stringent quality control analysis as follows: samples
showing reduced coverage and probes containing SNPs
were removed, and only probes with detection levels
above background across all samples were retained
(detection P < 0.01).
Panel identification, selection and classification
The UroMark panel was defined using pre-set criteria in
the training cohort (Table 1) as follows: in order for probes
to be considered as potential biomarker candidates, they
had to show no or very low methylation (β <10%) in nor-
mal urothelium, blood and non-cancer urine samples and
methylation (β) of >50% in bladder cancer. A <10% cut
was selected from the analysis of beta values from fully
unmethylated control DNA. The probes passing this filter
were subsequently used to generate a classifier using a
random forest model.
The random forest classification model was selected
as it has been shown to be effective with a limited num-
ber of predictors (i.e. number of loci being compared)
in comparison with the number of training points (i.e. the
number of samples within the training cohort) [35]. The
random forest model was implemented through the
Bioconductor package CAReT (version 6.0-24) [35]. To
define a robust classifier, the following steps were imple-
mented: (A) A random selection of 80% of cases and con-
trols was selected as training cohort, with the remaining
20% retained to form a test set; (B) a random forest model
was developed for each training cohort; (C) a predicted
class (cancer or normal) was generated for each corre-
sponding test cohort; (D) for each iteration, the model
and area under the curve (AUC) value were noted; (E)
steps A–D were repeated 100 times, and the optimal
model was determined by comparison of each AUC value.
The optimal model was fixed and applied to all subse-
quent analysis.
Comparative testing of UroMark assay and classifiers
based on the best performing 3, 5 and 10 loci panels was
performed by a simple logistic regression model to cal-
culate probabilities of each combination. The perform-
ance of individual loci is shown in Additional file 1:
Table S4. The best performing combination of 3, 5 and
10 probes were selected based on a false positive rate of
<10% in the training cohort. Area under the ROC
(receiver operating characteristic) curve for the UroMark
assay and best performing 3, 5 and 10 marker panels
were calculated using the Bioconductor package pROC
(version 1.7). Loci were involved in OTX1, ONECUT2,
ZNF154, TBX2 and ZIC4.
RainDance microdroplet PCR of urinary DNA
RainDrop BS-seq was performed as previously described
[27, 28]. Primers were designed for targeted regions in
Table 2 Patient characteristics of urine samples used in the
assessment of the UroMark assay
Cohort 3 (N = 86) Cohort 4 (N = 188)
Cancer 52 55
Age 62.4 (22–111) 65.2 (36–90)
Gender
Male/Female 49/13 43/12
Ta–T1 27 28
T2–T4 25 27
Low grade 17 24
High grade 35 31
Non-cancer 34 133
Age 62 (27–89) 63 (29–144)
Gender
Male/Female 20/14 82/51
Haematuria status
Micro 4 67
Macro 11 51
Unknown 19 15
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Additional file 2: Table S1. For microdroplet PCR,
7.20 μL of bisulfite-treated urinary DNA was added to
4.70 μL of 10× High-Fidelity Buffer (Invitrogen),
1.80 μL of 50 mM MgSO4 (Invitrogen), 1.62 μL of
10 mM dNTP solution mix (NEB), 3.60 μL of 4 mol L−1
betaine solution (Sigma-Aldrich), 3.60 μL of droplet
stabiliser (RainDance Technologies), 1.80 μL of 100%
dimethyl sulfoxide (Sigma-Aldrich) and 0.72 μL of 5 U/
μL Platinum Taq Polymerase High-Fidelity (Invitrogen),
to a total volume of 25 μL. The sample plate was sealed
using an ALPS 50V microplate heat sealer (Thermo
Scientific). The bisulfite-treated genomic DNA template
mix was then applied to a fully automated Thunder-
Storm system (RainDance Technologies) following the
manufacturer’s instructions. In brief, primer panel
droplets (MethylSeq Solution, RainDance Technologies)
were dispensed to a microfluidic chip. The DNA tem-
plate mix was converted into droplets within the micro-
fluidic chip. The primer pair droplets and template
droplets were then paired together in a 1:1 ratio. The
paired droplets passed through an electric field indu-
cing the discrete droplets to coalesce into a single PCR
droplet (26 pL); approximately one million PCR drop-
lets are collected per sample.
The PCR droplets were processed in a PTC-225 ther-
mocycler (MJ Research) as follows: 94 °C for 2 min; 55 cy-
cles of 94 °C for 30 s, 54 °C for 45 s and 68 °C for 80 s;
followed by 68 °C for 10 min; 4 °C until further processing.
The ramp rate was set to 1 °C per second. Following PCR
amplification, 70 μL of droplet destabilizer (RainDance
Technologies) were added to each sample to break the
PCR droplet emulsion and release the amplicons con-
tained within the droplets. The solution was mixed well
and incubated for 15 min at room temperature. The
samples were purified using Agencourt AMPure XP
magnetic beads (Beckman Coulter) following the manu-
facturer’s protocol. For each sample, 234 μL of beads
were used. The samples were eluted from magnetic
beads in 40 μL of EB Buffer. The integrity and concen-
tration (fragment range 120–300 bp) of purified ampli-
con DNA were assessed using a High Sensitivity DNA
Kit (Agilent Technologies) on a 2100 Bioanalyzer
(Agilent Technologies).
Universal PCR
To prepare the samples for high-throughput DNA se-
quencing, Illumina adapter sequences and unique bar-
codes were introduced through an additional PCR step.
Fifteen nanograms of purified amplified DNA were
added to 3.25 μL of 10× High-Fidelity Buffer, 0.88 μL of
50 mM MgSO4, 0.88 μL of 10 mM dNTP solution mix,
2.50 μL of 4 mol L−1 betaine solution, 1.25 μL of 100%
dimethyl sulfoxide, 0.50 μl of 5 U/μL Platinum Taq
Polymerase High-Fidelity and 2.5 μL of 5 μM PCR
primers, to a total volume of 25 μL. All primer se-
quences are provided in Additional file 3: Table S2.
The samples were amplified as follows: 94 °C for
2 min; 10 cycles of 94 °C for 30 s, 56 °C for 45 s and
68 °C for 60 s; followed by 68 °C for 10 min; 4 °C until
further processing. DNA was purified using a MinElute
PCR Purification Kit (QIAGEN) according to the man-
ufacturer’s protocol. Purified DNA was eluted in 10 μL
of EB Buffer. The samples were quantified (fragment
range 100–400 bp and 220–500 bp) using a DNA 1000
Kit on a 2100 Bioanalyzer. Fifty nanograms of each
sample were subsequently pooled. The resulting se-
quencing library was quantified using a Qubit dsDNA
BR Assay Kit.
High-throughput DNA sequencing
The pooled sequencing library (12 pmol L−1) and cus-
tom sequencing primers (0.5 μmol L−1) were applied to
a MiSeq 300-cycle PE consumable cartridge (Illumina)
according to the manufacturer’s protocol. The DNA
sequences of the custom sequencing primers are pro-
vided in Additional file 4: Table S3. The sequencing
was performed on a MiSeq DNA sequencer (Illumina)
using 150 bp paired end reads.
Data and statistical analyses
Sequencing adapters were trimmed from the raw sequen-
cing reads using the fastq-mcf tool of ea-utils v1.1.2-537.
Trimmed sequencing data were mapped to an in silico
bisulfite-converted human reference genome (GRCh37)
using Bismark v0.7.12 [36]. Methylation information was
extracted using the methylation extractor tool of Bismark
v0.7.12 [36]. Targeted DNA sequencing analyses were per-
formed using the R package TEQC v3.2.0 [37].
Results
Genome-wide DNA methylation profiling to define
bladder cancer-specific loci
We performed genome-wide methylation profiling of
86 bladder cancers and 30 normal urothelium (Table 1)
using the Infinium Human 450K DNA methylation
array. From these data, we defined a panel of 432
bladder cancer-specific loci, which are unmethylated in
non-cancer samples and methylated in the majority of
cancer tissue (Fig. 1a).
To derive a bladder cancer-specific DNA methylation
signature, which would allow classification of independ-
ent samples, we used a random forest model which re-
sulted in a signature consisting of 150 CpG loci (Fig. 1b)
which on the test set, resulted in a cross-validated sensi-
tivity of 100% and specificity of 100% for the detection
of cancer (Additional file 5: Figure S1A, B).
Methylation data from a second cohort of 199 patients
(144 high-grade muscle-invasive, 35 non-muscle-invasive
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Fig. 1 a Heatmap of DNA methylation state of the 432 bladder cancer-specific MVPs from the discovery cohort: tumour in red (n = 86) and normal
urothelium in blue (n = 30). b Heatmap of the 150 loci defined in the UroMark assay: non-cancer urine in light blue (n = 10), normal urothelium in dark
blue (n = 30), bladder cancer in red (n = 86) and blood in green (n = 489). The heatmap colour scale depicts methylation values ranging from 0% (yellow)
to 100% (blue)
Fig. 2 Heatmap of the 150 UroMark loci: independent primary tumours (n = 179) of high grade in red (n = 144) and low grade in green (n = 35);
normal bladder in blue (n = 20)
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cancers and 20 normal cases (Table 1, cohort 2)) was used
to test the sensitivity of the marker panel for detection of
bladder cancer. The panel correctly classified all bladder
cancers (Fig. 2), with a resulting sensitivity and specificity
of 100% (Additional file 5: Figure S2A and S2B).
Validation of the detection panel
The 150 loci panel is designed for the detection of
bladder cancer in urinary sediment cells. To test the
assay in this setting, DNA from urinary sediment cells
was extracted from a subset of 86 cases, consisting of
52 bladder cancer patients and 34 non-cancer control
patients (Table 2, cohort 3). The presence of cancer
was then predicted using the fixed random forest clas-
sifier defined from the discovery cohort above, and
each sample was given a binary classification, cancer
present/cancer absent. Figure 3 shows the receiver op-
erator characteristics (ROC) for the UroMark assay on
DNA from voided urine samples which achieved a sen-
sitivity of 95% and specificity of 96% (AUC = 97%,
negative predictive value (NPV) = 97%). Cystoscopy
was used as the reference standard, and therefore, bio-
marker positive cystoscopy negative cases were defined
as false positives.
Developing the UroMark assay as a high-throughput NGS
assay
The UroMark assay is designed as a high-throughput
microdroplet-based PCR amplification system using
RainDrop BS-seq [27, 28]. The encapsulation of distinct
PCR reactions in microdroplets combined with NGS
allows the targeted bisulfite sequencing of a large num-
ber of unique regions in parallel from limited substrate
[27, 28]. We have previously validated this technology
and have shown it to be highly correlated with the Infi-
nium Human 450K DNA methylation array and also
shown its utility with low template input [27, 28].
We designed a bisulfite-converted primer library to
determine the methylation state of the 150 selected gen-
omic loci. Primers were designed to interrogate both
Watson and Crick strands independently where possible.
Bisulfite-treated urinary DNA was subsequently used as
a template for the microdroplet-based PCR amplification
reaction with a RainDance ThunderStorm system.
To validate the UroMark assay using RainDrop BS-seq,
we tested a second independent cohort of 188 cases
(cohort 4). DNA from urinary sediment cells was ob-
tained from 55 patients with bladder cancer, and 133
patients confirmed to be cancer-free on cystoscopy and
upper track imaging (Table 2, cohort 4). All samples
analysed had >30 ng of DNA; NGS data was analysed
as described [27, 28]. The fraction of aligned sequen-
cing reads mapping to the target amplicons ranged
between 94.5–98.7% across the sample cohort. All
amplicons of the panel amplified across the sample co-
hort. The average sequence coverage across all samples
was 1254-fold (range 123–2673).
A methylation score for each of the 150 loci were gen-
erated using the Bismark algorithm [9]. The pre-trained
fixed random forest classification model, as above, was
then used to predict the presence or absence of cancer
for RainDrop BS-Seq data. Using these data, the Uro-
Mark assay detected bladder cancer with a sensitivity of
96% and specificity of 97% (AUC = 96% (CI 92.66%–
100); NPV = 98%) (Fig. 4a).
Combining all urine samples processed using the
UroMark (n = 274), including non-cancer (n = 167) and
bladder cancer (n = 107) (cohort 3 and cohort 4), the
UroMark assay predicted the presence of bladder cancer
with an AUC of 97% and a NPV of 97% (Fig. 4b).
Comparison with small panels
To understand how the performance of the UroMark
assay was compared to the best performing single markers
and small-marker panels, combinations of the top per-
forming three, five and ten biomarkers were identified
from the training cohort. Any individual marker was posi-
tive based on a simple methylation cut-off generated for
each locus referenced on the methylation value of normal
urothelium. The best performing markers were combined
into panels of three, five or ten loci along with the loci
involved in previously published in regression-based pre-
dictive classifiers developed to explore the potential for
these ‘oligo’ panels [19, 21–23].
Fig. 3 Receiver operator characteristic (ROC) evaluating the
performance of the UroMark model for the detection of bladder
cancer in urine
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These data show that although both single markers
and small panels perform reasonably well alone or in
combination (Table 3, Additional file 5: Figure S3), with
AUCs ranging from 66–75% for small panels and 54–
72% for single markers, the sensitivity to detect cancer
using an oligo panel approach is limited and below a de-
tection level desirable for clinical utility to replace
cystoscopy.
Discussion
This study reports the development and proof of principle
testing of high-throughput target bisulphite sequencing
assay, UroMark, to interrogate cancer epigenetic alter-
ations in urinary sediment. A non-invasive test for the
detection of bladder cancer has the potential to revolu-
tionise the diagnostic pathway, for both haematuria
investigations and improved surveillance strategies for
patients with established disease. In proof of concept test-
ing of a cohort of cancer and control urine samples, we
show that the high sensitivity and specificity obtained with
the UroMark assay has performance characteristics which
are similar to cystoscopy.
DNA methylation patterns are highly cancer cell-
specific, and the ontogenic stability of these epigenetic
events makes DNA methylation an ideal biomarker for
the detection and diagnosis of disease. Changes in glo-
bal DNA methylation patterns are a common feature of
neoplastic transformation and a frequent event in blad-
der cancer [16–18, 38]. Previous studies have shown
that changes in DNA methylation status of bladder
cancer, both non-muscle-invasive and muscle-invasive
bladder cancers as well as normal urothelium are reflected
in the methylation status of urinary sediment cells and as
such, could be a useful diagnostic marker [16, 17, 38].
Although methylation-based detection assays (alone or in
combination with somatic mutation) show promise with
sensitivity to detect bladder cancer between 65–98%, they
have not as yet progressed into clinical practise [8, 17, 19,
21–24]. The number of loci that can be included within a
Fig. 4 Receiver operator characteristic (ROC) evaluating the performance of the UroMark assay for the detection of bladder cancer in a 188 unique
urine samples from cohort 4 and b combined total of 274 urines run through the UroMark (red = cohort 3, black = cohort 4, green = combined)
Table 3 Test performance characteristics of small panels of
markers (3, 5 and 10) and single markers to detect bladder
cancer compared to the UroMark assay
UroMark UroMark Specificity Sensitivity NPV PPV AUC
1 0.98 0.97 1 0.9829
Top panels Top 10 0.91 0.91 0.72 0.94 0.7525
Top 5 0.89 0.77 0.66 0.91 0.6993
Top 3 0.86 0.72 0.61 0.88 0.6604
Top individual
marker
Marker_1 0.89 0.62 0.54 0.88 0.6173
Marker_2 0.91 0.75 0.67 0.93 0.7197
Marker_3 0.83 0.73 0.59 0.85 0.6319
Marker_4 0.89 0.84 0.73 0.91 0.7321
Marker_5 0.91 0.57 0.53 0.91 0.6213
Marker_6 0.94 0.59 0.54 0.94 0.6438
Marker_7 0.86 0.79 0.67 0.90 0.6932
Marker_8 0.74 0.81 0.66 0.83 0.6382
Marker_9 0.86 0.51 0.47 0.83 0.5457
Marker_10 0.94 0.69 0.61 0.95 0.693
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panel using traditional technology to detect methylation
and the low volume of substrate DNA that can be ex-
tracted from urinary sediment for large numbers of
candidates have until recently been a limiting factor for
assay development. Furthermore, the reliance on uni-
form methylation (low inter-tumour variability) as well
as the effect of intra-tumour heterogeneity indicate that
the performance of ‘oligo panel’ assays will be limited
across a wide spectrum of stage and grade [39]. Novel
technologies, combining next-generation bisulfite se-
quencing with large-scale multiplex PCR, overcome
these issues allowing the interrogation of a large panel
of epigenetic biomarkers from a single sample, and as
such, we believe this represents a paradigm shift in de-
velopment strategy [27, 28].
In order to annotate the epigenetic alterations involved
in bladder cancer and to define a biomarker panel, we
have carried out the largest unbiased genome-wide DNA
methylation screens of bladder cancer to date. Although
our initial discovery panel was predominately high-grade
disease, it is of note that the majority or >98% of the al-
terations present in high-grade bladder cancer were con-
firmed in low-grade disease. Using stringent criteria, we
have defined a detection panel of 150 CpG loci which is
relatively large but was necessary to detect all of the 260
bladder cancers included in the assay development cohort
based on individual methylation expression and represent-
ing the spectrum of stage and grade. We believe the large
panel and customised random forest analysis pipeline
to retain specificity and sensitivity can overcome short-
comings of traditional biomarker panels which are
constrained by technology. The use of NGS, particu-
larly in cancer diagnosis, is becoming routine, and con-
sistent with this, we demonstrate the potential for a
large-scale highly multiplexed next-generation assay,
the performance characteristics being highly sensitive
and specific, can be achieved with a NPV comparable
to cystoscopy.
The current assay was developed to answer the spe-
cific question around the primary diagnosis of bladder
cancer in patients with haematuria and has yet to be
tested in the recurrence setting. Urinary biomarker as-
says for the detection of recurrent bladder cancer have
generally fared less well than in the primary diagnosis
setting with sensitivities ranging from 56–80%. This low
sensitivity for the detection of recurrent disease is likely
due to low urinary concentration of tumour cells har-
bouring the small number specific alterations analysed
or the analytical sensitivity of the assays used. The large
panel of loci utilised in the UroMark panel in combin-
ation with the analytical sensitivity potential achieved
with next generation sequencing may also allow the
UroMark assay to compare favourably with cystoscopy
in the recurrent setting.
The next stage will be the robust testing (Phase III
biomarker road map [40]) of this assay in two MRC-
funded trials (NCT02676180 and NCT0278428) which
are currently recruiting across multiple sites in the UK.
In the current development studies, we used a mixed
cohort of tumours and non-cancer controls from vari-
ous sources. The objective of the Phase III studies is to
determine the NPV of UroMark for the detection of
bladder cancer in a population of patients referred for
investigation of haematuria.
Conclusions
In this proof of concept study, we show the potential
utility of a highly multiplex bisulphite sequencing assay
for the detection of bladder cancer from urinary sedi-
ment. The use of a non-invasive assay which rules out
the presence of cancer with a high degree of certainty
has the potential to revolutionise the treatment of blad-
der cancer.
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